Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Relapsed or Refractory Waldenström Macroglobulinemia
NCT03187262Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2017
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in Waldenström macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03187262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187262.